SIC 2836 - Biological Products, Except Diagnostic Substances
SIC 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
View full description Collapse full description
Establishments primarily engaged in the production of bacterial and virus vaccines, toxoids, and analogous products (such as allergenic extracts), serums, plasmas, and other blood derivatives for human or veterinary use, other than in vitro and in vivo diagnostic substances. Included in this industry are establishments primarily engaged in the production of microbiological products for other uses.
Establishments primarily engaged in manufacturing in vitro and in vivo diagnostic substances are classified in Industry 2835.
Explore the industry hierarchy
Drill down to explore more specific industries.
Industry trends
The Biological Products industry (NAICS 2836), which excludes diagnostic substances, is experiencing several significant trends. Firstly, there is a strong emphasis on advanced biotechnology applications, including the use of CRISPR and other gene-editing technologies. These innovations are driving the development of personalized medicine and targeted therapies, reflecting a shift towards more precise and effective treatments.
Another notable trend is the growing interest in biopharmaceutical outsourcing, as companies seek to leverage specialized expertise and reduce time-to-market. Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) are playing increasingly crucial roles in the development and production processes.
Additionally, the industry is seeing substantial investment in bioprocessing technologies, which aim to enhance efficiency and scalability. Continuous bioprocessing and single-use technologies are gaining traction, offering flexible and cost-effective solutions for biologics production.
The regulatory environment is also evolving, with agencies like the FDA and EMA providing clearer guidelines on biosimilars and novel biologics. This regulatory clarity is expected to accelerate market entry and foster innovation.
Looking ahead, the forecast for the industry is positive, with sustained growth anticipated over the next few years. The market for biologics is projected to expand due to rising demand for innovative therapies and the increased prevalence of chronic diseases. Furthermore, advancements in biotechnology will likely continue to drive transformative changes, positioning the industry for a robust future.
- Investment in renewable energy and grid modernization continues to accelerate.
- Regulatory changes and sustainability initiatives are shaping long-term growth.
- Operational efficiency and technology adoption are key focus areas.
Get the Full Industry Report
In-depth analysis, 50+ financial ratios, 4-year trends, and industry forecasts.